Completed PHASE1/PHASE2 INTERVENTIONAL NCT00174538

Codeine in Sickle Cell Disease

The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease

Sponsor: PriCara, Unit of Ortho-McNeil, Inc.

Updated 5 times since 2017 Last updated: Jun 29, 2011 Started: Mar 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Sickle Cell Disease, this trial is completed. The trial is conducted by PriCara, Unit of Ortho-McNeil, Inc. and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PriCara, Unit of Ortho-McNeil, Inc.

Data source: PriCara, Unit of Ortho-McNeil, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States